- Global Pharma News & Resources

The Worldwide Chronic Obstructive Pulmonary Disease Treatment Industry is Expected to Reach $104 Billion by 2027 -

DUBLIN--(BUSINESS WIRE)--The "Chronic Obstructive Pulmonary Disease Treatment Market Research Report by Drug Type, Product, Test, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to's offering.

The Global Chronic Obstructive Pulmonary Disease Treatment Market size was estimated at USD 67.08 billion in 2021, USD 72.06 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.59% to reach USD 104.08 billion by 2027

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Chronic Obstructive Pulmonary Disease Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Chronic Obstructive Pulmonary Disease Treatment Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Chronic Obstructive Pulmonary Disease Treatment Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Chronic Obstructive Pulmonary Disease Treatment Market?

4. What is the competitive strategic window for opportunities in the Global Chronic Obstructive Pulmonary Disease Treatment Market?

5. What are the technology trends and regulatory frameworks in the Global Chronic Obstructive Pulmonary Disease Treatment Market?

6. What is the market share of the leading vendors in the Global Chronic Obstructive Pulmonary Disease Treatment Market?

7. What modes and strategic moves are considered suitable for entering the Global Chronic Obstructive Pulmonary Disease Treatment Market?

Market Dynamics


  • Increasing environmental pollution
  • Rapidly growing tobacco and cigarette consumption causing prevalence's of pulmonary disease
  • Rising global expenditure on medicine and personal care and technological advancements


  • Presence of generic drugs in the market
  • Lack of proper awareness about the effect of chronic obstructive pulmonary diseases


  • Research and development activities


  • Increased pricing pressures and patent expiries

Companies Mentioned

  • Abbott Laboratories
  • Ache Laboratorios Farmaceuticos S.A
  • Adamis Pharmaceuticals Corporation
  • Almirall, S.A.
  • Aquinox Pharmaceuticals
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biomarck Pharmaceuticals, Ltd.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Orion Corporation
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 07-Jul-2022